The growing problem of antibacterial resistance resulted in an increased interest in fosfomycin, especially its parenteral formulation. We reviewed fosfomycin safety profile using the Food and Drug
INTRODUCTION
Fosfomycin, discovered in Spain in 1969, is a cell wall-acting antibacterial drug that inhibits the formation of N-acetylmuramic acid, a precursor of peptidoglycan. Fosfomycin has been available in Europe since the 1970s and was approved in the United States in 1996 [1] .
In the US, it is approved as a 3-g sachet of fosfomycin tromethamine to be given orally as a single dose for uncomplicated cystitis due to susceptible strains of Escherichia coli and Enterococcus faecalis. In Europe, fosfomycin is also available as fosfomycin disodium for intravenous (IV) administration and is used for various infections at doses of 12-16 g/day (up to 24 g/day), divided into 3-4 doses.
In vitro, fosfomycin is active against [2] . Some extended spectrum beta-lactamase-producing strains of E. coli and K. pneumoniae are susceptible to fosfomycin [3, 4] . Fosfomycin is variably active against Pseudomonas aeruginosa and Acinetobacter spp. [2, 4, 5] . The oral formulation of fosfomycin is considered to have a favorable safety profile with gastrointestinal disturbances being the most commonly associated adverse event [1, 2] . An IV formulation of fosfomycin, fosfomycin disodium, is associated with a high sodium intake which could be a limitation in patients with heart failure or those on hemodialysis [2] . Adverse reactions such as angioedema, aplastic anemia, cholestatic jaundice, and hepatic necrosis have been reported postmarketing [1] . Because of the growing problem of antibacterial resistance, there has been an increased interest in fosfomycin use, especially its parenteral formulations [6] . This review summarizes the safety profile of fosfomycin using the Food and Drug Administration (FDA) Adverse Event (AE) Reporting System (FAERS) and published literature with an emphasis on AEs associated with its parenteral formulations.
METHODS
The FAERS database was queried for domestic and foreign cases of AEs reported with oral or IV formulations. The FAERS contains information on AE and medication error reports submitted to FDA. AEs and medication errors are coded to terms in the Medical Dictionary for Regulatory Activities (MedDRA) terminology.
We conducted three FAERS searches. The first search included reports regardless of whether fosfomycin was implicated as the primary suspect. The period for the search was from 1996 through September 2012. Data retrieved by this search were subjected to a disproportionality analysis (henceforth referred to as a 'data mining analysis'). This analysis aims to detect over-represented associations of drug-event combinations in the FAERS. The The EBGM value provides a stable estimate of the relative reporting ratio of any AE for a particular drug relative to all other drugs and AEs in FAERS. MGPS also calculates lower and upper 90% confidence intervals (CI) for the EBGM scores, denoted as EB05 and EB95, respectively. The higher the EBGM value for a particular drug-AE combination, the higher is the reporting association between that drug and AE in the database. Drug-AE pairs with an EB05 (lower bound of the 90% CI for the EBGM) [1 indicate AEs that occur above the expected rate. Furthermore, one may estimate that events with an EB05 [2 occur at least twice the expected ratio relative to the other drugs and events in the database. For our data mining analysis, we selected reports of events with an EB05 [1.
Subsequently, we conducted a FAERS search for reports of AEs where fosfomycin was considered to be the primary suspect [8] .
A separate FAERS search was conducted for all cases of possible bone marrow toxicity with the terms of agranulocytosis, neutropenia, febrile neutropenia, aplastic anemia, bone marrow failure, aplasia pure red cell, and pancytopenia associated with the use of fosfomycin. This separate query was prompted by a case of aplastic anemia that was reported to the FDA. Aplastic anemia was defined as a combination of hemoglobin level \10 g/dl, segmented polymorphonuclear and band cells count \1.5 9 10 9 /l, platelet count \100 9 10 9 / l), and histological evidence of decreased cellularity, absence of infiltration and absence of significant fibrosis on bone marrow examination [9] .
We then supplemented the results of the FAERS searches by the literature review of the safety profile of fosfomycin. The review was conducted by searching articles in English with the term ''fosfomycin'' via PubMed. We conducted a systematic review aiming to evaluate for possible imbalances in the frequency of AEs associated with fosfomycin as compared to other antibacterial drugs with the focus on fosfomycin AEs over-represented in the data-mining analysis and on safety signals associated with IV administration of fosfomycin.
The reports of clinical trials, meta-analyses, systematic reviews, and case reports of AEs associated with fosfomycin were selected. Individual trials were selected if they included greater than 10 patients. For parenteral formulations of fosfomycin, all clinical trials were selected for analysis and for oral formulations only prospective comparative trials were selected. References of the selected articles were also reviewed. The database was most recently accessed on July 9, 2015.
Compliance with Ethics Guidelines
This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors. No identifiable patient data were provided or accessed. Review of the events with EB05 score from [1 to 2 revealed that many of these events were related to hypersensitivity reactions including anaphylactic reaction (n = 5), anaphylactic shock (n = 4), toxic epidermal necrolysis (n = 4), dermatitis exfoliative (n = 6), acute generalized exanthematous pustulosis (n = 3), drug hypersensitivity (n = 6), hypersensitivity (n = 8), vascular purpura (n = 3), rash maculopapular (n = 6), rash erythematous (n = 6), dermatitis allergic (n = 3), and face edema (n = 8).
RESULTS
Subsequent FAERS query for events where fosfomycin was considered to be the primary suspect identified a total of 146 reports. There were 31 domestic and 115 foreign reports; in 132 cases fosfomycin was given by oral and in 5 cases by IV or intramuscular routes; the route of administration was not reported in 9 reports. In the majority of cases, fosfomycin was used for the treatment of urinary tract infections (UTI) (n = 131). itraconazole and ciprofloxacin. One week after receiving fosfomycin the patient was found to have a decrease in platelet count to 70 9 10 9 /l.
On day 17 after fosfomycin administration platelet count was 27 9 10 9 /l, WBC was 1.7 9 10 9 /l and hematocrit was 33. Bone marrow aspiration reported changes ''consistent with aplastic anemia''. Filgrastim and epoetin alfa were administered and hematological abnormalities resolved by day 44 after fosfomycin dosing.
Literature Search
The Norfloxacin 9 3 days GI disorders-1 (6%) GI disorders-1 (6%) AEs associated with oral administration of fosfomycin are presented in Table 6 . The majority of these trials studied a single dose of fosfomycin for the treatment of uncomplicated Table 6 .
One placebo-controlled trial for prophylaxis of recurrent uncomplicated UTI evaluated safety of a prolonged exposure to oral fosfomycin [33] . The trial compared 166 females treated with 3 g of oral fosfomycin every 10 days for 6 months with 155 subjects treated with placebo. After a follow-up of 360 days including 6 interim evaluations there were 2 (1%) AEs (rash and mild dyspnea) in the treatment arm as compared with 4 events in the placebo arm. Hematology and chemistry laboratory parameters at the end of the study did not show any significant difference between the two arms.
Trials conducted in pediatric population included 3 retrospective trials of parenteral [11, 44, 49, 50] . Overall, no specific safety issues related to the use of fosfomycin in children were identified.
Five trials of a total of 291 patients reported on the use of fosfomycin in pregnancy for the treatment of asymptomatic bacteriuria [36, 51, 52, 54, 56] . One of these trials in 153 patients specifically indicated that no serious fetal AEs were observed [36] .
Our review of the literature also identified several reviews reporting on the efficacy and safety of fosfomycin. A meta-analysis of 27 randomized controlled trials compared fosfomycin (n = 2188) with other antibacterial drugs (n = 2052) for the treatment of cystitis [61] . The authors reported that fosfomycin had a comparable safety profile with the evaluated comparators in non-pregnant women, mixed and pediatric populations, and was associated with fewer AEs in pregnant women [61] .
Information on the efficacy and safety of fosfomycin was provided by the Japan Research Committee of Fosfomycin in a report evaluating 1191 and 503 patients who received oral and IV fosfomycin, respectively [62] . There have been four case reports of anaphylaxis associated with fosfomycin administration [66] [67] [68] . All reported cases were associated with oral formulations of fosfomycin and occurred within minutes to an hour after fosfomycin intake.
DISCUSSION
Fosfomycin has been in clinical use for about 25 years and its safety profile has been previously described [6, 61, 69] . Our review did not identify new safety concerns related to fosfomycin. The most frequent AEs associated with parenteral administration of fosfomycin included rash, peripheral phlebitis, hypokalemia, and gastrointestinal disorders.
Gastrointestinal disorders were the most common
AEs associated with oral administration.
While the initial results of data mining for all reports of AEs associated with fosfomycin in the FAERS database revealed a higher than expected frequency of reports of agranulocytosis, liver injury, severe skin reactions, and pseudomembranous colitis, subsequent searches for adverse reactions implicating fosfomycin as the primary suspect as well as the literature review did not suggest an association of the drug with these AEs. Serious AEs of cytopenias, liver toxicities, and hypersensitivity reactions were not more frequent in fosfomycin-treated patients in comparative trials and were not common in non-comparative trials.
A separate search and detailed analysis of all FAERS reports of cytopenia identified one case that met pre-defined criteria of aplastic anemia that was associated with the use of oral Hypokalemia was the most common AE in this study (26%). Another publication reports on the case of fosfomycin-associated heart failure that promptly resolved after the discontinuation of the drug [70] .
Although, fosfomycin was suspected to be the cause of fetal toxicities in 7 cases in the Limitations of the literature review are related to a small number of randomized comparative prospective trials for parenteral fosfomycin and that in 5 out of 7 of these trials the drug was given for up to 3 days for prophylaxis of surgical site infection [10, [13] [14] [15] [16] . Only 64 patients were treated with fosfomycin in randomized prospective comparative trials [12, 17] . Another comparative trial was retrospective and enrolled 70 patients in the fosfomycin arm [11] . 
CONCLUSION

